INTRODUCTION Myeloid neoplasms (MNs) are a group of clonal disorders originating from hematopoietic stem or progenitor cells. This category encompasses several malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), and overlap syndromes, such as MDS/MPN (1). With the widespread use of targeted therapy and immunotherapy, the prognosis and survival rates of patients with hematological malignancies have significantly improved.